|
1
|
Obregón-Mendoza MA, Meza-Morales W, Rodríguez-Hernández KD, Estévez-Carmona MM, Pérez-González LL, Tavera-Hernández R, Ramírez-Apan MT, Barrera-Hernández D, García-Olivares M, Monroy-Torres B, Nieto-Camacho A, Chávez MI, Sánchez-Obregón R, Enríquez RG. The Antitumoral Effect In Ovo of a New Inclusion Complex from Dimethoxycurcumin with Magnesium and Beta-Cyclodextrin. Int J Mol Sci 2024; 25:4380. [PMID: 38673967 PMCID: PMC11050057 DOI: 10.3390/ijms25084380] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2024] [Revised: 04/05/2024] [Accepted: 04/09/2024] [Indexed: 04/28/2024] Open
Abstract
Breast cancer is one of the leading causes of death in the female population because of the resistance of cancer cells to many anticancer drugs used. Curcumin has cytotoxic activities against breast cancer cells, although it has limited use due to its poor bioavailability and rapid metabolic elimination. The synthesis of metal complexes of curcumin and curcuminoids is a relevant topic in the search for more active and selective derivatives of these molecular scaffolds. However, solubility and bioavailability are concomitant disadvantages of these types of molecules. To overcome such drawbacks, the preparation of inclusion complexes offers a chemical and pharmacologically safe option for improving the aqueous solubility of organic molecules. Herein, we describe the preparation of the inclusion complex of dimethoxycurcumin magnesium complex (DiMeOC-Mg, (4)) with beta-cyclodextrin (DiMeOC-Mg-BCD, (5)) in the stoichiometric relationship 1:1. This new inclusion complex's solubility in aqueous media phosphate buffer saline (PBS) was improved by a factor of 6x over the free metal complex (4). Furthermore, 5 affects cell metabolic rate, cell morphology, cell migration, induced apoptosis, and downregulation of the matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9), interleukin-6 (IL-6), and signal transducer and activator of transcription-3 (STAT3) expression levels on MD Anderson metastasis breast-231 cancer (MDA-MB-231) cell lines. Results of an antitumor assay in an in ovo model showed up to 30% inhibition of tumor growth for breast cancer (MDA-MB-231) when using (5) (0.650 mg/kg dose) and 17.29% inhibition with the free homoleptic metal complex (1.5 mg/kg dose, (4)). While the formulation of inclusion complexes from metal complexes of curcuminoids demonstrates its usefulness in improving the solubility and bioavailability of these metallodrugs, the new compound (5) exhibits excellent potential for use as a therapeutic agent in the battle against breast cancer.
Collapse
Affiliation(s)
- Marco A. Obregón-Mendoza
- Instituto de Química, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico; (M.A.O.-M.); (W.M.-M.); (K.D.R.-H.); (L.L.P.-G.); (R.T.-H.); (M.T.R.-A.); (B.M.-T.); (A.N.-C.); (M.I.C.); (R.S.-O.)
| | - William Meza-Morales
- Instituto de Química, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico; (M.A.O.-M.); (W.M.-M.); (K.D.R.-H.); (L.L.P.-G.); (R.T.-H.); (M.T.R.-A.); (B.M.-T.); (A.N.-C.); (M.I.C.); (R.S.-O.)
| | - Karla Daniela Rodríguez-Hernández
- Instituto de Química, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico; (M.A.O.-M.); (W.M.-M.); (K.D.R.-H.); (L.L.P.-G.); (R.T.-H.); (M.T.R.-A.); (B.M.-T.); (A.N.-C.); (M.I.C.); (R.S.-O.)
| | - M. Mirian Estévez-Carmona
- Departamento de Farmacia, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, M. Wilfrido Massieu SN, U. A. Zacatenco, Mexico City 07738, Mexico;
| | - Leidys L. Pérez-González
- Instituto de Química, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico; (M.A.O.-M.); (W.M.-M.); (K.D.R.-H.); (L.L.P.-G.); (R.T.-H.); (M.T.R.-A.); (B.M.-T.); (A.N.-C.); (M.I.C.); (R.S.-O.)
| | - Rosario Tavera-Hernández
- Instituto de Química, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico; (M.A.O.-M.); (W.M.-M.); (K.D.R.-H.); (L.L.P.-G.); (R.T.-H.); (M.T.R.-A.); (B.M.-T.); (A.N.-C.); (M.I.C.); (R.S.-O.)
| | - María Teresa Ramírez-Apan
- Instituto de Química, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico; (M.A.O.-M.); (W.M.-M.); (K.D.R.-H.); (L.L.P.-G.); (R.T.-H.); (M.T.R.-A.); (B.M.-T.); (A.N.-C.); (M.I.C.); (R.S.-O.)
| | - David Barrera-Hernández
- Departamento de Biología de la Reproducción “Dr. Carlos Gual Castro”, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City 14080, Mexico; (D.B.-H.); (M.G.-O.)
| | - Mitzi García-Olivares
- Departamento de Biología de la Reproducción “Dr. Carlos Gual Castro”, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City 14080, Mexico; (D.B.-H.); (M.G.-O.)
| | - Brian Monroy-Torres
- Instituto de Química, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico; (M.A.O.-M.); (W.M.-M.); (K.D.R.-H.); (L.L.P.-G.); (R.T.-H.); (M.T.R.-A.); (B.M.-T.); (A.N.-C.); (M.I.C.); (R.S.-O.)
| | - Antonio Nieto-Camacho
- Instituto de Química, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico; (M.A.O.-M.); (W.M.-M.); (K.D.R.-H.); (L.L.P.-G.); (R.T.-H.); (M.T.R.-A.); (B.M.-T.); (A.N.-C.); (M.I.C.); (R.S.-O.)
| | - María Isabel Chávez
- Instituto de Química, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico; (M.A.O.-M.); (W.M.-M.); (K.D.R.-H.); (L.L.P.-G.); (R.T.-H.); (M.T.R.-A.); (B.M.-T.); (A.N.-C.); (M.I.C.); (R.S.-O.)
| | - Rubén Sánchez-Obregón
- Instituto de Química, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico; (M.A.O.-M.); (W.M.-M.); (K.D.R.-H.); (L.L.P.-G.); (R.T.-H.); (M.T.R.-A.); (B.M.-T.); (A.N.-C.); (M.I.C.); (R.S.-O.)
| | - Raúl G. Enríquez
- Instituto de Química, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico; (M.A.O.-M.); (W.M.-M.); (K.D.R.-H.); (L.L.P.-G.); (R.T.-H.); (M.T.R.-A.); (B.M.-T.); (A.N.-C.); (M.I.C.); (R.S.-O.)
| |
Collapse
|
|
2
|
Xu H, Hu X, Li J, Nie Z, Kang S, Liu H, Wang Y, Jia X, Lyu Z. The Inverse Association of Serum Magnesium with Papillary Thyroid Cancer in Thyroid Nodules: a Cross-Sectional Survey Based on Thyroidectomy Population. Biol Trace Elem Res 2022; 201:3279-3289. [PMID: 36227448 DOI: 10.1007/s12011-022-03448-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/21/2022] [Accepted: 10/04/2022] [Indexed: 11/02/2022]
Abstract
Magnesium is considered to play a role in preventing cancer. However, the association between serum magnesium and papillary thyroid cancer (PTC) remains unknown. We retrospectively reviewed records of all patients who underwent thyroidectomy with thyroid nodules confirmed pathologically as benign nodule or PTC at our institution from January 2016 to December 2020. Data including demographic characteristics, laboratory tests, and pathological features were analyzed in 5709 adult patients eventually. The subjects with benign nodules had a higher mean serum magnesium level than those with PTC (P < 0.001), and the proportions of PTCs decreased across quartiles of serum magnesium within the normal range. After adjustment for confounders, patients with the lowest quartile of serum magnesium had a higher prevalence of PTC than those with the highest quartile (OR = 1.421, 95%CI: 1.125-1.795, P for trend = 0.005), and the risk of PTC was 0.863 (95%CI: 0.795-0.936) for a per-SD change in serum magnesium. The contribution of serum magnesium remained in subgroup analysis (P for interaction for all analyses > 0.05). Based on the ROC curve, the cut-off value of serum magnesium used to differentiate benign nodules from PTCs was 935 μmol/L. Combining serum magnesium with other clinical indicators can improve the efficacy of predicting PTC. Our results showed that lower serum magnesium within the normal range was associated with a greater risk of PTC among patients with thyroid nodules considering thyroidectomy. Serum magnesium may be an independent protective factor against PTC and provide additional information on the odds of malignancy in uncertain thyroid nodules in combination with other clinical factors.
Collapse
Affiliation(s)
- Huaijin Xu
- Department of Endocrinology, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, 100853, Beijing, China
- School of Medicine, Nankai University, Tianjin, 300071, China
| | - Xiaodong Hu
- Department of Endocrinology, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, 100853, Beijing, China
| | - Jiefei Li
- Department of Endocrinology, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, 100853, Beijing, China
- School of Medicine, Nankai University, Tianjin, 300071, China
| | - Zhimei Nie
- Department of Endocrinology, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, 100853, Beijing, China
| | - Shaoyang Kang
- Department of Endocrinology, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, 100853, Beijing, China
| | - Hongzhou Liu
- Department of Endocrinology, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, 100853, Beijing, China
| | - Yuhan Wang
- Department of Endocrinology, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, 100853, Beijing, China
| | - Xiaomeng Jia
- Center for Endocrine Metabolism and Immune Disease, Beijing Luhe Hospital, Capital Medical University, Beijing, 101149, China
| | - Zhaohui Lyu
- Department of Endocrinology, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, 100853, Beijing, China.
- School of Medicine, Nankai University, Tianjin, 300071, China.
| |
Collapse
|
|
3
|
Magnesium in Aging, Health and Diseases. Nutrients 2021; 13:nu13020463. [PMID: 33573164 PMCID: PMC7912123 DOI: 10.3390/nu13020463] [Citation(s) in RCA: 96] [Impact Index Per Article: 32.0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2020] [Revised: 01/26/2021] [Accepted: 01/28/2021] [Indexed: 12/15/2022] Open
Abstract
Several changes of magnesium (Mg) metabolism have been reported with aging, including diminished Mg intake, impaired intestinal Mg absorption and renal Mg wasting. Mild Mg deficits are generally asymptomatic and clinical signs are usually non-specific or absent. Asthenia, sleep disorders, hyperemotionality, and cognitive disorders are common in the elderly with mild Mg deficit, and may be often confused with age-related symptoms. Chronic Mg deficits increase the production of free radicals which have been implicated in the development of several chronic age-related disorders. Numerous human diseases have been associated with Mg deficits, including cardiovascular diseases, hypertension and stroke, cardio-metabolic syndrome and type 2 diabetes mellitus, airways constrictive syndromes and asthma, depression, stress-related conditions and psychiatric disorders, Alzheimer's disease (AD) and other dementia syndromes, muscular diseases (muscle pain, chronic fatigue, and fibromyalgia), bone fragility, and cancer. Dietary Mg and/or Mg consumed in drinking water (generally more bioavailable than Mg contained in food) or in alternative Mg supplements should be taken into consideration in the correction of Mg deficits. Maintaining an optimal Mg balance all through life may help in the prevention of oxidative stress and chronic conditions associated with aging. This needs to be demonstrated by future studies.
Collapse
|